Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Scottyon Mar 06, 2020 3:37pm

51 Views

Post# 30777119

RE:RE:Looking4Doubles Please Respond

Thanks for the reply, but you didn't answer my question.

I agree with the potential of KLY, that's why I'm invested (rather heavily) and am concerened.

I don't care what Penny thinks, I have all his accounts blocked.

Simply:

1. Why aren't you concerned about the inevitable dilution which will absolutely crush your position.
2. Do you believe financing will come from elsewhere? If so, why? There is no evidence for it, do you just believe it will happen?

Bullboard Posts

Advancing an underexplored area of the Yukon with the same geology as B.C’.s Golden Triangle